Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Jul 9, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new mobile phone program designed to help people with cancer take their oral anticancer medicines correctly and manage any symptoms they may experience. The program also aims to improve communication between patients and their healthcare providers outside of regular clinic visits and offers support for financial or social needs, as well as help with understanding health information. The study will include about 30 patients who speak either English or Spanish.
To join the study, participants must be 18 years or older, have any type or stage of cancer, and have recently started or be about to start a new oral anticancer treatment. They also need to be receiving care at specific cancer clinics and own a smartphone to receive text messages related to the study. Participants will use the mobile program to track their medication use and symptoms, and they will receive support based on their needs. This study will help researchers learn how well this mobile health tool works and what might make it easier or harder for patients to use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must speak English or Spanish
- • Must be 18 years of age or older
- • Have a diagnosis of any type and stage of cancer
- • Have a new prescription for an oral anticancer therapy (OAT) initiated within the last 90 days or planned to start within the next 15 days
- • Be receiving treatment at UCI Chao Family Comprehensive Cancer Center-affiliated oncology clinics
- • Own a smartphone and be willing to receive study-related text messages.
- Exclusion Criteria:
- • Have an Eastern Cooperative Oncology Group (ECOG) performance status greater than 2
- • Be medically or cognitively unable to give consent or participate in the study
- • Be participating in another clinical trial that monitors adherence or symptoms related to the newly prescribed OAT
About University Of California, Irvine
The University of California, Irvine (UCI) is a leading research institution renowned for its commitment to advancing health and medical knowledge through innovative clinical trials. With a robust infrastructure for clinical research, UCI fosters interdisciplinary collaboration among its esteemed faculty and researchers, aiming to translate scientific discoveries into effective therapeutic solutions. The university prioritizes ethical standards and participant safety while addressing critical healthcare challenges across various fields, including cancer, neurology, and public health. UCI's dedication to excellence in research and education positions it as a pivotal contributor to the advancement of clinical science and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Orange, California, United States
Yorba Linda, California, United States
Irvine, California, United States
Newport Beach, California, United States
Newport Beach, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported